Analysis of the resistance profile of microorganisms in the pre-pandemic and Covid-19 pandemic period
DOI:
https://doi.org/10.17058/reci.v15i3.20199Keywords:
Drug resistance, Covid-19, Cross infection, Intensive care unitsAbstract
Background and Objectives: With the pandemic caused by SARS-CoV-2, the intense empirical use of antibiotic therapy endorsed selective pressure driving microbial resistance. To understand the profile of ATB resistance in the hospital environment generates support for the rational use of it. This study aimed to analyze the resistance profile of microorganisms in patients admitted to intensive care units of Amazonas before and during the Covid-19 pandemic. Methods: This is a quantitative, observational, and retrospective study conducted between 2019 and 2021. Based on the database provided by Dr. Rosemary Costa Pinto Health Surveillance Foundation, it was possible to identify the isolated microorganisms, compare the microbial resistance profile during the research period, and relate it to the main types of mandatory notification infections found in blood cultures and urine cultures. The data were organized in Microsoft Excel spreadsheets and subjected to a descriptive analysis according to their epidemiological significance. Results: 26 microorganisms were classified over the three years, with a higher prevalence of carbapenem-resistant and cephalosporin-resistant gram-negative bacteria; however, there was a higher incidence of oxacillin-resistant gram-positive bacteria. Conclusion: Empirical antimicrobial treatment was used to minimize the high mortality in health services during the coronavirus pandemic, but its approach lacked good clinical reasoning from the professionals of the multidisciplinary team. By avoiding the indiscriminate use of antibiotics, the cost and expenses of unnecessary public and private resources are also avoided, also slowing down the speed of spread of microbial resistance.
Downloads
References
1. Mudenda S, Witika BA, Sadiq MJ, et al. Self-medication and its Consequences during & after the Coronavirus Disease 2019 (COVID-19) Pandemic: A Global Health Problem. EUR J ENV PUBLIC HLT. 2021;5(1):em0066. https://doi.org/10.29333/ejeph/9308
2. Naveca F, Nascimento V, Souza V, et al. COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1. 2021. https://doi.org/10.21203/RS.3.RS-275494/V1.
3. BRASIL. Agência Nacional de Vigilância Sanitária. Prevenção de infecções por microrganismos multirresistentes em serviços de saúde [Internet] 1ª Ed. 2021. Disponível em: https://pncq.org.br/wp-content/uploads/2021/03/manual-prevencao-de-multirresistentes7.pdf
4. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jan 15; 46(2), 155-164. https://doi.org/10.1086/524891
5. Organização Pan-Americana da Saúde (OPAS) [Internet]. Resistência Antimicrobiana. 2019. Disponível em: https://www.paho.org/pt/topicos/resistencia-antimicrobiana.
6. World Health Organization (WHO) [internet]. Genebra: Antimicrobial Resistance fact sheets-What is antimicrobial resistance?. Disponível em: https://www.who.int/features/qa/75/en/
7. BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). NOTA TÉCNICA GVIMS/GGTES/DIRE3/ANVISA n° 01: Orientações para vigilância das Infecções Relacionadas à assistência à Saúde (IRAS) e resistência microbiana (RM) em serviços de saúde. Brasília: Ministério da Saúde; 2023. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/notas-tecnicas/2020/nota-tecnica-gvims-ggtes-dire3-anvisa-no-01-2023-orientacoes-para-vigilancia-das-infeccoes-relacionadas-a-assistencia-a-saude-iras-e-resistencia-microbiana-.
8. BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). NOTA TÉCNICA GVIMS/GGTES/DIRE3/ANVISA n° 02: Notificação dos Indicadores Nacionais das Infecções Relacionadas à Assistência à Saúde (IRAS) e Resistência Microbiana (RM). Brasília: Ministério da Saúde; 2023. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/notas-tecnicas/2020/nota-tecnica-gvims-ggtes-dire3-anvisa-no-02-2023-notificacao-dos-indicadores-nacionais-das-infeccoes-relacionadas-a-assistencia-a-saude-iras-e-resistencia-m.
9. BRASIL. Agência Nacional de Vigilância Sanitária (ANVISA). NOTA TÉCNICA GVIMS/GGTES/DIRE3/ANVISA n° 03: Critérios Diagnósticos das infecções relacionadas à assistência à saúde (IRAS) de notificação nacional obrigatória. Brasília: Ministério da Saúde; 2023. Disponível em: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/notas-tecnicas/2020/nota-tecnica-gvims-ggtes-dire3-anvisa-no-03-2023-criterios-diagnosticos-das-infeccoes-relacionadas-a-assistencia-a-saude-iras-de-notificacao-nacional-obriga.
10. Rawson TM, Moore LS, Castro-Sanchez E, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. Journal of antimicrobial chemotherapy, 2020 Jul 1. 75(7), 1681-1684. https://doi.org/10.1093/jac/dkaa194
11. Wicky PH, Niedermann MS, Timsit JF. Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact? Crit Care. 2021 Apr 21;25(1):153. https://doi.org/10.1186/s13054-021-03571-z
12. Fattorini L, Creti R, Palma C, et al. Unit of Antibiotic Resistance and Special Pathogens; Unit of Antibiotic Resistance and Special Pathogens of the Department of Infectious Diseases, Istituto Superiore di Sanità, Rome. Bacterial coinfections in COVID-19: an underestimated adversary. Ann Ist Super Sanita. 2020 Jul-Sep;56(3):359-364. https://doi.org/10.4415/ann_20_03_14
13. Valença C, Jain S, Freire de Carvalho N, et al. RESISTÊNCIA MICROBIANA ASSOCIADA AO COVID-19. CGCBS [Internet]. 17 de novembro de 2022; 7(3):11. Disponível em: https://periodicos.set.edu.br/cadernobiologicas/article/view/11039.
14. Nassar Júnior AP, Bezerra IL, Malheiro DT, et al. Patient-level costs of central line-associated bloodstream infections caused by multidrug-resistant microorganisms in a public intensive care unit in Brazil: a retrospective cohort study. Rev Bras Ter Intensiva. 2023 Mar 3;34(4):529-533. https://doi.org/10.5935/0103-507x.20220313-pt.
15. Lima CSSC, Lima HAR, Silva CSAG. Late-onset neonatal infections and bacterial multidrug resistance. Revista Paulista de Pediatria [online]. 2023, v. 41, e2022068. https://doi.org/10.1590/1984-0462/2023/41/2022068
16. Zuo XS, Liu YH, Hu K. Epidemiology and risk factors of candidemia due to|Candida parapsilosisin an intensive care unit. Revista do Instituto de Medicina Tropical de São Paulo [online]. 2021, v. 63, e20. https://doi.org/10.1590/s1678-9946202163020
17. BRASIL. Ministério da Saúde. Coronavírus: Atendimentos e fatores de risco [internet]. 22 jun 2023. Disponível em: https://www.gov.br/saude/pt-br/coronavirus/atendimento-tratamento-e-fatores-de-risco.
18. Sousa MF, Reis LGO, Baracho VS, et al. Microbiological and microstructural analysis of indwelling bladder catheters and urinary tract infection prevention. Rev Esc Enferm USP. 2022;56:e20210552. https://doi.org/10.1590/1980-220x-reeusp-2021-0552
19. Silva JL, Silva MR, Ferreira SM, et al. Resistência microbiana a medicamentos em uma Instituição de Longa Permanência para Idosos. Acta Paul Enferm. 2022;35:eAPE03751. https://doi.org/10.37689/acta-ape/2022AO03751
20. Van Dulm E, Tholen ATR, Pettersson A, et al. High prevalence of multidrug resistant Enterobacteriaceae among residents of long term care facilities in Amsterdam, the Netherlands. PLoS One. 2019 Sep 12;14(9):e0222200. https://doi.org/10.1371/journal.pone.0222200
Published
Issue
Section
License
Copyright (c) 2025 Esther Pereira Abensur, Adriany da Rocha Pimentão, Vinícius Moura de Araújo , Albe Dias Batista, Eidie Souza de Queiroz, Maria Luiza Silva dos Santos , Pedro Eduardo Garcia de Andrade , Elielza Guerreiro Menezes, Evelyn Cesar Campelo, Timóteo Tadashi Watanabe

This work is licensed under a Creative Commons Attribution 4.0 International License.
The author must state that the paper is original (has not been published previously), not infringing any copyright or other ownership right involving third parties. Once the paper is submitted, the Journal reserves the right to make normative changes, such as spelling and grammar, in order to maintain the language standard, but respecting the author’s style. The published papers become ownership of RECI, considering that all the opinions expressed by the authors are their responsibility. Because we are an open access journal, we allow free use of articles in educational and scientific applications provided the source is cited under the Creative Commons CC-BY license.